These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17076637)

  • 1. Chemical and biological factors in the control of Brucella and brucellosis.
    Gamazo C; Lecároz MC; Prior S; Vitas AI; Campanero MA; Irache JM; Blanco-Prieto MJ
    Curr Drug Deliv; 2006 Oct; 3(4):359-65. PubMed ID: 17076637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omp31 plays an important role on outer membrane properties and intracellular survival of Brucella melitensis in murine macrophages and HeLa cells.
    Verdiguel-Fernández L; Oropeza-Navarro R; Basurto-Alcántara FJ; Castañeda-Ramírez A; Verdugo-Rodríguez A
    Arch Microbiol; 2017 Sep; 199(7):971-978. PubMed ID: 28382472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress on Brucellosis.
    Deng Y; Liu X; Duan K; Peng Q
    Curr Med Chem; 2019; 26(30):5598-5608. PubMed ID: 29745323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brucella - Virulence Factors, Pathogenesis and Treatment.
    Głowacka P; Żakowska D; Naylor K; Niemcewicz M; Bielawska-Drózd A
    Pol J Microbiol; 2018 Jun; 67(2):151-161. PubMed ID: 30015453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Brucella Infection Induces Selective and Persistent Interferon Gamma-Dependent Alterations of Marginal Zone Macrophages in the Spleen.
    Machelart A; Khadrawi A; Demars A; Willemart K; De Trez C; Letesson JJ; Muraille E
    Infect Immun; 2017 Nov; 85(11):. PubMed ID: 28808159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of some new antibiotics in treating experimental brucellosis].
    Maletskaia OV
    Antibiot Khimioter; 2002; 47(11):13-7. PubMed ID: 12698575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modern chemotherapy for brucellosis in humans.
    Hall WH
    Rev Infect Dis; 1990; 12(6):1060-99. PubMed ID: 2267485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano and microparticle drug delivery systems for the treatment of Brucella infections.
    Razei A; Javanbakht M; Hajizade A; Heiat M; Zhao S; Aghamollaei H; Saadati M; Khafaei M; Asadi M; Cegolon L; Keihan AH
    Biomed Pharmacother; 2023 Dec; 169():115875. PubMed ID: 37979375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides.
    Fountain MW; Weiss SJ; Fountain AG; Shen A; Lenk RP
    J Infect Dis; 1985 Sep; 152(3):529-35. PubMed ID: 2411828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a method for evaluating intracellular antibiotic efficacy in Brucella abortus-infected Mono Mac 6 monocytes.
    Valderas MW; Barrow WW
    J Antimicrob Chemother; 2008 Jan; 61(1):128-34. PubMed ID: 18024491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections.
    Lueth P; Haughney SL; Binnebose AM; Mullis AS; Peroutka-Bigus N; Narasimhan B; Bellaire BH
    J Control Release; 2019 Jan; 294():288-297. PubMed ID: 30572034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future trends in human brucellosis treatment.
    Pappas G; Papadimitriou P; Christou L; Akritidis N
    Expert Opin Investig Drugs; 2006 Oct; 15(10):1141-9. PubMed ID: 16989591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline.
    Seleem MN; Jain N; Pothayee N; Ranjan A; Riffle JS; Sriranganathan N
    FEMS Microbiol Lett; 2009 May; 294(1):24-31. PubMed ID: 19493005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for human brucellosis.
    Al-Tawfiq JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):109-20. PubMed ID: 18251668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early events and implication of F-actin and annexin I associated structures in the phagocytic uptake of Brucella suis by the J-774A.1 murine cell line and human monocytes.
    Kusumawati A; Cazevieille C; Porte F; Bettache S; Liautard JP; Sri Widada J
    Microb Pathog; 2000 Jun; 28(6):343-52. PubMed ID: 10839971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.
    Bosch J; Liñares J; López de Goicoechea MJ; Ariza J; Cisnal MC; Martin R
    J Antimicrob Chemother; 1986 Apr; 17(4):459-61. PubMed ID: 2940209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can brucella endocarditis be treated successfully with medical therapy alone?
    Mohandas N; Balasubramanian R; Prasad SB
    Trop Doct; 2009 Apr; 39(2):123-4. PubMed ID: 19299306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment.
    Fugier E; Pappas G; Gorvel JP
    Expert Rev Mol Med; 2007 Dec; 9(35):1-10. PubMed ID: 18088444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on antimicrobial susceptibility of Brucella in a city].
    Zuo SW; Ni ZL; Yao YB; Yang RS; Wang SK; Zhou YH
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Dec; 35(12):939-941. PubMed ID: 29495161
    [No Abstract]   [Full Text] [Related]  

  • 20. Nocodazole treatment interrupted Brucella abortus invasion in RAW 264.7 cells, and successfully attenuated splenic proliferation with enhanced inflammatory response in mice.
    Reyes AW; Hop HT; Arayan LT; Huy TX; Min W; Lee HJ; Chang HH; Kim S
    Microb Pathog; 2017 Feb; 103():87-93. PubMed ID: 28017899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.